Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Elsamitrucin · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| Elsamitrucin | DRUG | - |
Inclusion Criteria: * Relapsed or Refractory mantle cell lymphoma and/or CLL/SLL except Burkitt's, Burkitt's like or HIV-associated lymphoma * at least one prior cytotoxic chemotherapy regimens * measurable disease * adequate bone marrow, liver and kidney function * ECOG PS 0-2 Exclusion Criteria:...
Elsamitrucin is an investigational small molecule being studied for the treatment of Mantle Cell Lymphoma, a type of non-Hodgkin's lymphoma. It is also being evaluated in patients with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma. The drug is currently in clinical development and has not been approved by the FDA.
Elsamitrucin is being developed by Assertio Holdings, Inc., a biopharmaceutical company. The company's stock is traded under the ticker symbol ASRT. Assertio is conducting clinical trials to evaluate the safety and efficacy of Elsamitrucin in patients with certain types of lymphoma.
Elsamitrucin is in Phase 2 clinical development. It has completed one Phase 2 trial, which was an uncontrolled study in patients with relapsed or refractory non-Hodgkin's lymphoma. The drug is still investigational and has not received FDA approval for any indication.
Elsamitrucin has been studied in one completed clinical trial with the identifier NCT00090090. This Phase 2 trial evaluated Elsamitrucin (also known as SPI 28090) in 114 patients with relapsed or refractory non-Hodgkin's lymphoma, including Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia. The trial was conducted in the United States.
Yes, Elsamitrucin is also known as SPI 28090. The clinical trial NCT00090090 used the name SPI 28090 to refer to the drug. This alternative name may appear in scientific literature and clinical trial records, so patients and researchers should be aware that both names refer to the same investigational drug.